Caliper’s Revenues Shoot Up, but Losses Stay Flat in Q1
Caliper Life Sciences last week reported a three-fold revenue increase year-over-year for the first quarter of 2004, while losses remained stable. Revenues were $16.9 million, up from $5.6 million during the same period last year. This increase was mainly due to revenues from Zymark, which Caliper acquired last July.
R&D expenses decreased to $6.5 million, from $9.4 million during the same quarter in 2003.